Domov › Shizofrenija › Illinois
Klinične študije za Shizofrenija v Illinois
26 študij za Shizofrenija išče udeležence na lokacijah v Illinois.
Mesta v Illinois
Uradno besedilo študije (angleško)
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- The University of Chicago, Chicago
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 18–59 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07853807Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
Vključevanje udeležencevFaza 1
Starost 18–55 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07686263Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
Vključevanje udeležencevFaza 3
Starost 5–17 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07114874A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Vključevanje udeležencevFaza 3
Starost 5–17 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 18–55 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07410507A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Vključevanje udeležencevFaza 3
Starost 13–17 · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
Vključevanje udeležencevFaza 1
Starost 18–55 · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
Vključevanje udeležencevFaza 2
Starost 18–65 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
Vključevanje udeležencevFaza 3
Starost 10–17 · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
Vključevanje udeležencevFaza 2
Starost 18–65 · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
Vključevanje udeležencevOpazovalna študija
Starost 18–40 · Vsi spoli · Posodobljeno 20. jul. 2026 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
Vključevanje udeležencevFaza 2
Starost 18–55 · Vsi spoli · Posodobljeno 23. jun. 2026 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
Vključevanje udeležencevFaza 4
Starost 18–65 · Vsi spoli · Posodobljeno 3. jun. 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
Vključevanje udeležencevFaza 4
Starost 18–60 · Vsi spoli · Posodobljeno 11. maj 2026 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
Vključevanje udeležencevOpazovalna študija
Starost 18–40 · Vsi spoli · Posodobljeno 10. mar. 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 6. mar. 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 12. jan. 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
Vključevanje udeležencevFaza 2
Starost 21–55 · Vsi spoli · Posodobljeno 26. dec. 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci
Starost 18–65 · Vsi spoli · Posodobljeno 19. dec. 2024 · NCT05184335Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.